Claims
- 1. A method for the treatment of bacterial infections, comprising:administering parentally in a host a composition comprising an effective amount of at least one lytic enzyme produced by a bacteria infected with a bacteriophage specific for said bacteria and a carrier for delivering said lytic enzyme to the to the site of the infection.
- 2. The method according to claim 1, wherein the at least one lytic enzyme is for the treatment of Pseudomonas.
- 3. The method according to claim 1, wherein the at least one lytic enzyme is for the treatment of Streptococcus.
- 4. The method according to claim 1, wherein the at least one lytic enzyme is for the treatment of Staphylococcus.
- 5. The method according to claim 1, wherein the at least one lytic enzyme is for the treatment of Clostridium.
- 6. The method according to claim 1, wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.
- 7. The method according to claim 6, wherein the buffer maintains the pH of the composition at the range between about 5.5 and about 7.5.
- 8. The method according to claim 6, wherein said buffer comprises a reducing reagent.
- 9. The method according to claim 8, wherein said reducing reagent is dithiothreitol.
- 10. The method according to claim 6, wherein said buffer comprises a metal chelating reagent.
- 11. The method according to claim 10, wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.
- 12. The method according to claim 6, wherein said buffer is a citrate-phosphate buffer.
- 13. The method according to claim 1, further comprising a bactericidal or bacteriostatic agent as a preservative.
- 14. The method according to claim 1, wherein said at least one lytic enzyme is lyophilized.
- 15. The method according to claim 1, wherein said therapeutic agent is administered intravenously.
- 16. The method according to claim 1, wherein said therapeutic agent is administered intramuscularly.
- 17. The method according to claim 1, wherein said therapeutic agent is administered subcutaneously.
- 18. The method according to claim 1, wherein the therapeutic agent further comprises at least one complementary agent which potentiates the bactericidal activity of the lysine enzyme, said complementary agent being selected from the group consisting of penicillin, synthetic penicillins, bacitracin, methicillin, cephalosporin, polymyxin, cefaclor, Cefadroxil, cefamandole nafate, cefazolin, cefixime, cefinetazole, cefonioid, cefoperazone, ceforanide, cefotanme, cefotaxime, cefotetan, cefoxitin, cefpodoxime proxetil, ceftazidime, ceftizoxime, ceftriaxone, cefriaxone moxalactam, cefuroxime, cephalexin, cephalosporin C, cephalosporin C sodium salt, cephalothin, cephalothin sodium salt, cephapirin, cephradine, cefuroximneaxetil, dihydratecephalothin, moxalactam, and chelating agents in an amount effective to synergistically enhance the therapeutic effect of the lysin enzyme.
- 19. The method according to claim 1, wherein said carrier comprises of distilled water, a saline solution, albumin, a serum, and any combinations thereof.
- 20. The method according to claim 1, wherein said carrier further comprises preservatives.
- 21. The method according to claim 20, wherein said preservatives comprise p-hydroxybenzoates.
- 22. The method according to claim 1, wherein said carrier comprises an isotonic solution for an injection, said isotonic solution comprising a compound selected from group consisting of sodium chloride, dextrose, mannitol, sorbitol, lactose, phosphate buffered saline, gelatin, albumin, a vasoconstriction agent and combinations.
- 23. The method according to claim 22, wherein said further carrier further comprises DMSO.
Parent Case Info
The following application is a continuation in part of U.S. patent application Ser. No. 09/395,636, filed Sep. 14, 1999, now U.S. Pat. No. 6,056,954, issued May 2, 2000, which is a continuation in part of U.S. patent application Ser. No. 08/962,523, filed Oct. 31, 1997, now U.S. Pat. No. 5,997,862, issued Dec. 7, 1999.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5985271 |
Fischetti et al. |
Nov 1999 |
|
5997862 |
Fischetti et al. |
Dec 1999 |
|
6056954 |
Fischetti et al. |
May 2000 |
|
6056955 |
Fischetti et al. |
May 2000 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
09/395636 |
Sep 1999 |
US |
Child |
09/482992 |
|
US |
Parent |
08/962523 |
Oct 1997 |
US |
Child |
09/395636 |
|
US |